Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Jelena Bešević; Marc J Gunter; Renée T Fortner; Konstantinos K Tsilidis; Elisabete Weiderpass; N Charlotte Onland-Moret; Laure Dossus; Anne Tjønneland; Louise Hansen; Kim Overvad; Sylvie Mesrine; Laura Baglietto; Françoise Clavel-Chapelon; Rudolf Kaaks; Krasimira Aleksandrova; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Christina Bamia; Giovanna Masala; Claudia Agnoli; Rosario Tumino; Fulvio Ricceri; Salvatore Panico; H Bas Bueno-de-Mesquita; Petra H Peeters; Mie Jareid; J Ramón Quirós; Eric J Duell; María-José Sánchez; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte; Joana A Dias; Emily Sonestedt; Annika Idahl; Eva Lundin; Nicholas J Wareham; Kay-Tee Khaw; Ruth C Travis; Sabina Rinaldi; Isabelle Romieu; Elio Riboli; Melissa A Merritt

doi:10.1038/bjc.2015.377

Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Jelena Bešević
, Marc J Gunter
, Renée T Fortner
, Konstantinos K Tsilidis
, Elisabete Weiderpass
, N Charlotte Onland-Moret
, Laure Dossus
, Anne Tjønneland
, Louise Hansen
, Kim Overvad
, Sylvie Mesrine
, Laura Baglietto
, Françoise Clavel-Chapelon
, Rudolf Kaaks
, Krasimira Aleksandrova
, Heiner Boeing
, Antonia Trichopoulou
, Pagona Lagiou
, Christina Bamia
, Giovanna Masala

Claudia Agnoli, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H Bas Bueno-de-Mesquita, Petra H Peeters, Mie Jareid, J Ramón Quirós, Eric J Duell, María-José Sánchez, Nerea Larrañaga, María-Dolores Chirlaque, Aurelio Barricarte, Joana A Dias, Emily Sonestedt, Annika Idahl, Eva Lundin, Nicholas J Wareham, Kay-Tee Khaw, Ruth C Travis, Sabina Rinaldi, Isabelle Romieu, Elio Riboli, Melissa A Merritt

Forskningsoutput: Tidskriftsbidrag › Artikel › Peer review

32 Citeringar (Scopus)

Sammanfattning

BACKGROUND: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.

METHODS: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.

RESULTS: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.

CONCLUSIONS: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

Originalspråk	Engelska
Sidor (från-till)	1622-31
Antal sidor	10
Tidskrift	British Journal of Cancer
Volym	113
Nummer	11
DOI	https://doi.org/10.1038/bjc.2015.377
Status	Publicerad - 2015-dec.-01
Externt publicerad	Ja

FN:s SDG:er

Detta resultat bidrar till följande hållbara utvecklingsmål:

SDG 3 – God hälsa och välbefinnande

Åtkomst av dokument

10.1038/bjc.2015.377

Citera det här

Bešević, J., Gunter, M. J., Fortner, R. T., Tsilidis, K. K., Weiderpass, E., Onland-Moret, N. C., Dossus, L., Tjønneland, A., Hansen, L., Overvad, K., Mesrine, S., Baglietto, L., Clavel-Chapelon, F., Kaaks, R., Aleksandrova, K., Boeing, H., Trichopoulou, A., Lagiou, P., Bamia, C., ... Merritt, M. A. (2015). Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. British Journal of Cancer, 113(11), 1622-31. https://doi.org/10.1038/bjc.2015.377

@article{28e79df0dff64eac88f32f8185cc4524,

title = "Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study",

abstract = "BACKGROUND: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.METHODS: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95\% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.RESULTS: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9\%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95\% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95\% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.CONCLUSIONS: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.",

keywords = "Adult, Age Factors, Aged, Aged, 80 and over, Breast Feeding, Carcinoma, Ovarian Epithelial, Contraceptives, Oral/therapeutic use, Estrogen Replacement Therapy, Europe/epidemiology, Female, Follow-Up Studies, Humans, Menarche, Menopause, Middle Aged, Neoplasms, Glandular and Epithelial/mortality, Ovarian Neoplasms/mortality, Parity, Survival Rate",

author = "Jelena Be{\v s}evi{\'c} and Gunter, \{Marc J\} and Fortner, \{Ren{\'e}e T\} and Tsilidis, \{Konstantinos K\} and Elisabete Weiderpass and Onland-Moret, \{N Charlotte\} and Laure Dossus and Anne Tj{\o}nneland and Louise Hansen and Kim Overvad and Sylvie Mesrine and Laura Baglietto and Fran{\c c}oise Clavel-Chapelon and Rudolf Kaaks and Krasimira Aleksandrova and Heiner Boeing and Antonia Trichopoulou and Pagona Lagiou and Christina Bamia and Giovanna Masala and Claudia Agnoli and Rosario Tumino and Fulvio Ricceri and Salvatore Panico and Bueno-de-Mesquita, \{H Bas\} and Peeters, \{Petra H\} and Mie Jareid and Quir{\'o}s, \{J Ram{\'o}n\} and Duell, \{Eric J\} and Mar{\'i}a-Jos{\'e} S{\'a}nchez and Nerea Larra{\~n}aga and Mar{\'i}a-Dolores Chirlaque and Aurelio Barricarte and Dias, \{Joana A\} and Emily Sonestedt and Annika Idahl and Eva Lundin and Wareham, \{Nicholas J\} and Kay-Tee Khaw and Travis, \{Ruth C\} and Sabina Rinaldi and Isabelle Romieu and Elio Riboli and Merritt, \{Melissa A\}",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/bjc.2015.377",

language = "English",

volume = "113",

pages = "1622--31",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "11",

}

Bešević, J, Gunter, MJ, Fortner, RT, Tsilidis, KK, Weiderpass, E, Onland-Moret, NC, Dossus, L, Tjønneland, A, Hansen, L, Overvad, K, Mesrine, S, Baglietto, L, Clavel-Chapelon, F, Kaaks, R, Aleksandrova, K, Boeing, H, Trichopoulou, A, Lagiou, P, Bamia, C, Masala, G, Agnoli, C, Tumino, R, Ricceri, F, Panico, S, Bueno-de-Mesquita, HB, Peeters, PH, Jareid, M, Quirós, JR, Duell, EJ, Sánchez, M-J, Larrañaga, N, Chirlaque, M-D, Barricarte, A, Dias, JA, Sonestedt, E, Idahl, A, Lundin, E, Wareham, NJ, Khaw, K-T, Travis, RC, Rinaldi, S, Romieu, I, Riboli, E & Merritt, MA 2015, 'Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study', British Journal of Cancer, vol. 113, nr. 11, s. 1622-31. https://doi.org/10.1038/bjc.2015.377

TY - JOUR

T1 - Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

AU - Bešević, Jelena

AU - Gunter, Marc J

AU - Fortner, Renée T

AU - Tsilidis, Konstantinos K

AU - Weiderpass, Elisabete

AU - Onland-Moret, N Charlotte

AU - Dossus, Laure

AU - Tjønneland, Anne

AU - Hansen, Louise

AU - Overvad, Kim

AU - Mesrine, Sylvie

AU - Baglietto, Laura

AU - Clavel-Chapelon, Françoise

AU - Kaaks, Rudolf

AU - Aleksandrova, Krasimira

AU - Boeing, Heiner

AU - Trichopoulou, Antonia

AU - Lagiou, Pagona

AU - Bamia, Christina

AU - Masala, Giovanna

AU - Agnoli, Claudia

AU - Tumino, Rosario

AU - Ricceri, Fulvio

AU - Panico, Salvatore

AU - Bueno-de-Mesquita, H Bas

AU - Peeters, Petra H

AU - Jareid, Mie

AU - Quirós, J Ramón

AU - Duell, Eric J

AU - Sánchez, María-José

AU - Larrañaga, Nerea

AU - Chirlaque, María-Dolores

AU - Barricarte, Aurelio

AU - Dias, Joana A

AU - Sonestedt, Emily

AU - Idahl, Annika

AU - Lundin, Eva

AU - Wareham, Nicholas J

AU - Khaw, Kay-Tee

AU - Travis, Ruth C

AU - Rinaldi, Sabina

AU - Romieu, Isabelle

AU - Riboli, Elio

AU - Merritt, Melissa A

PY - 2015/12/1

Y1 - 2015/12/1

N2 - BACKGROUND: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.METHODS: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.RESULTS: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.CONCLUSIONS: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

AB - BACKGROUND: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.METHODS: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.RESULTS: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.CONCLUSIONS: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

KW - Adult

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Breast Feeding

KW - Carcinoma, Ovarian Epithelial

KW - Contraceptives, Oral/therapeutic use

KW - Estrogen Replacement Therapy

KW - Europe/epidemiology

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Menarche

KW - Menopause

KW - Middle Aged

KW - Neoplasms, Glandular and Epithelial/mortality

KW - Ovarian Neoplasms/mortality

KW - Parity

KW - Survival Rate

U2 - 10.1038/bjc.2015.377

DO - 10.1038/bjc.2015.377

M3 - Article

C2 - 26554655

SN - 0007-0920

VL - 113

SP - 1622

EP - 1631

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Sammanfattning

FN:s SDG:er

Åtkomst av dokument

Fingeravtryck

Citera det här